Impact of renal impairment on chemotherapy-induced neutropenia in patients who are treated with trifluridine/thymidine phosphorylase inhibitor + bevacizumab for metastatic colorectal cancer: A retrospective study

Author:

Shibutani Masatsune1,Tanda Hideki1,Kasashima Hiroaki1,Fukuoka Tatsunari1,Kashiwagi Shinichiro1,Maeda Kiyoshi1

Affiliation:

1. Osaka Metropolitan University Graduate School of Medicine

Abstract

Abstract

Background: Although the phase III SUNLIGHT trial has demonstrated the survival benefit of the addition of bevacizumab (Bmab) to trifluridine/thymidine phosphorylase inhibitor (FTD/TPI), neutropenia, which frequently occurs during FDT/TPI + Bmab therapy, is a concern for clinicians. As TPI is excreted by the kidneys, the risk of adverse events is likely to be high in patients with an impaired renal function. This study aimed to investigate the relationship between renal impairment and the incidence of chemotherapy-induced neutropenia during FTD/TPI + Bmab therapy using real-world data. Methods: We retrospectively reviewed the medical records of 69 patients with metastatic colorectal cancer (mCRC) who were treated with FTD/TPI + Bmab for more than 28 days. Patients with renal impairment with an eGFR of 30-44 mL/min/1.73 m2 were defined as the G3b group. Results: Seven patients (10.1%) were classified into the G3b group. Among the 69 patients enrolled in this study, grade ≥3 neutropenia was observed in 34 patients (49.3%), and grade 4 neutropenia was observed in 9 patients (13.0%). Patients in the G3b group had an approximately 24% higher incidence of grade ≥3 neutropenia in comparison to others (71.4% vs. 46.8%), and the incidence of grade 4 neutropenia in the G3b group was significantly higher than that in others (42.9% vs. 9.7%, p=0.042). In an analysis limited to the G3b group, of the 5 patients who developed grade ≥3 neutropenia, four patients (80%) developed grade ≥3 neutropenia, and 2 (40%) developed grade 4 neutropenia within 30 days after initiation of FTD/TPI + Bmab therapy. However, the duration required for neutrophil count to recover to ≥1500 /mm3 and the treatment effects of the G3b group were comparable to those observed in other patients. Conclusion: FTD/TPI + Bmab therapy is associated with a high risk of severe neutropenia within 30 days of initiation, especially in patients with a decreased renal function.

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3